Table I.
Association between miR-711 expression level and clinical characteristics.
| miR-711 expressiona | |||
|---|---|---|---|
| Clinical characteristics | High, n (%) | Low, n (%) | P-value |
| All patients | 80 (100) | 81 (100) | |
| Age, years | 0.88 | ||
| >45 | 43 (54) | 45 (56) | |
| ≤45 | 37 (46) | 36 (44) | |
| Menopause | 0.82 | ||
| No | 42 (52) | 44 (54) | |
| Yes | 38 (48) | 37 (46) | |
| Pathological grade | 0.52 | ||
| I | 2 (3) | 5 (6) | |
| II | 68 (85) | 66 (82) | |
| III | 10 (13) | 10 (12) | |
| Estrogen receptor | 0.21 | ||
| Positive | 55 (69) | 48 (59) | |
| Negative | 25 (31) | 33 (41) | |
| Progesterone receptor | 0.58 | ||
| Positive | 48 (60) | 52 (64) | |
| Negative | 32 (40) | 29 (36) | |
| HER2 | 0.69 | ||
| Positive | 30 (37) | 28 (34) | |
| Negative | 50 (63) | 53 (66) | |
| Tumor stage | 0.23 | ||
| T1 | 17 (21) | 19 (24) | |
| T2 | 47 (59) | 55 (68) | |
| T3 | 14 (18) | 6 (7) | |
| T4 | 2 (3) | 1 (1) | |
| Node stage | 0.10 | ||
| N0 | 36 (45) | 47 (58) | |
| N1 | 23 (29) | 25 (31) | |
| N2 | 15 (19) | 6 (7) | |
| N3 | 6 (8) | 3 (4) | |
| TNM stage | 0.17 | ||
| I | 11 (14) | 15 (19) | |
| II | 43 (54) | 50 (62) | |
| III | 26 (33) | 16 (20) | |
| Radiotherapy | 0.35 | ||
| No | 16 (20) | 22 (27) | |
| Yes | 64 (80) | 59 (73) | |
| Chemotherapy | 0.86 | ||
| No | 24 (30) | 23 (28) | |
| Yes | 56 (70) | 58 (72) | |
χ2 test or Fisher's exact test used for P-value calculation.
a
Patients were divided into a high or low miR-711 expression group using the median expression level as the cut-off point (0.57). miR-711, microRNA-711; HER2, human epidermal growth factor receptor 2; TNM; tumor-node-metastasis.